The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder
Authors:
- Nazanin AryanNANazanin Aryan
- Hamid Reza BanafsheHBHamid Reza Banafshe
- Vahid FarniaVFVahid Farnia
- Jalal ShakeriJSJalal Shakeri
- Mostafa AlikhaniMAMostafa Alikhani
- Habibollah RahimiHRHabibollah Rahimi
- Mojtaba SehatMSMojtaba Sehat
- Peyman MamsharifiPeyman Mamsharifi
- Amir GhaderiAGAmir Ghaderi
- Abdollah OmidiAOAbdollah Omidi
Open Access
- 25 September 2020
- journal article
- research article
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 15 (1) , 1-9
Abstract
Background: Little evidence has examined the therapeutic effects of methylphenidate (MPH) and Matrix Model treatment on addiction severity, craving, relapse and mental health in people who use methamphetamine (PWUM). This study was conducted to determine the effects of MPH, Matrix Model treatment, and Matrix-MPH on addiction severity, craving, relapse and mental health in PWUM. Methods: This clinical trial was conducted among 100 patients with METH users. Participants were randomly divided into four groups who received: 1) 22 sessions of 45-min, twice a week for Matrix Model treatment (n = 25); 2) MPH 10 mg/day in the first month, 7.5 mg/day in the second month and 5 mg/day in the third month (n = 25); 3) Matrix Model treatment combined with MPH (n = 25); 4) control group (n = 25) for 12 weeks. Addiction severity, craving, relapse and mental status were evaluated at baseline and end-of-trial. Results: Matrix Model treatment combined with MPH significantly reduced MA craving (P < 0.001) and addiction severity (P < 0.001). In addition, Matrix Model treatment combined with MPH resulted in a significant increase of mental health (P = 0.001), compared with Matrix Model treatment, MPH, and control group. Also, negative METH urine test significantly increased in the Matrix Model treatment combined with MPH group compared with the other groups (P < 0.001). Conclusions: In conclusion, Matrix Model treatment combined with MPH for 12 weeks had beneficial effects on addiction severity, craving, relapse, and mental health in PWUM, compared with Matrix Model treatment, MPH, and control group. Trial registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical trials registration (http://www.irct.ir: IRCT20171105037245N1). Registration date: 9 December 2017.Keywords
Funding Information
- Kashan University of Medical Sciences (KAUMS/96128)
This publication has 54 references indexed in Scilit:
- Methylphenidate vs. resperidone in treatment of methamphetamine dependence: A clinical trialSaudi Pharmaceutical Journal, 2013
- Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trialAddiction, 2013
- Withdrawal symptoms in abstinent methamphetamine‐dependent subjectsAddiction, 2010
- Anxiety Disorders among Methamphetamine Dependent Adults: Association with Post‐Treatment FunctioningThe American Journal on Addictions, 2010
- Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot studyDrug and Alcohol Dependence, 2010
- Randomized Controlled Pilot Study of Cognitive-Behavioral Therapy in a Sample of Incarcerated Women With Substance Use Disorder and PTSDBehavior Therapy, 2009
- Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependenceCurrent Opinion in Psychiatry, 2009
- Depression Among Methamphetamine UsersJournal of Nervous & Mental Disease, 2009
- Self-efficacy for cocaine abstinence: Pretreatment correlates and relationship to outcomesAddictive Behaviors, 2008
- Psychometric properties of the General Health Questionnaire (GHQ‐12) in a German primary care sampleActa Psychiatrica Scandinavica, 1999